https://doi.org/10.4081/reumatismo.2019.1115
Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case
Submitted: 31 December 2017
Accepted: 6 September 2018
Published: 9 July 2019
Accepted: 6 September 2018
Abstract Views: 1127
PDF: 705
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Anti-tumor necrosis factor drugs are used routinely according to treatment guidelines for several chronic rheumatologic problems. However, a rare and usually unpredictable adverse drug reaction namely peripheral nervous system demyelination is being increasingly recognized. Biosimilars are gaining momentum especially in countries like India. Hence, we report a case of Guillain-Barré syndrome secondary to an etanercept biosimilar, probably the first case reported so far.
How to Cite
Shobha, V., Desai, A., & Matthew, T. (2019). Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case. Reumatismo, 71(2), 99–102. https://doi.org/10.4081/reumatismo.2019.1115
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- F.M. Perrotta, O. Addimanda, R. Ramonda, S. D’Angelo, E. Lubrano, A. Marchesoni, I. Olivieri, L. Punzi, C. Salvarani, A. Spadaro, Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs , Reumatismo: Vol. 66 No. 3 (2014)
- S.L. Bello, L. Serafino, C. Bonali, N. Terlizzi, C. Fanizza, C. Anecchino, G. Lapaldula, Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents , Reumatismo: Vol. 64 No. 5 (2012)
- A. Minelli, A. Vaona, Effectiveness of cognitive behavioral therapy in the treatment of fibromyalgia syndrome: a meta-analytic literature review , Reumatismo: Vol. 64 No. 3 (2012)
- A. Loi, S. Lisci, A. Denotti, A. Cauli, Bone mineral density in women on long-term mud-bath therapy in a Salus per Aquam (SPA) environment , Reumatismo: Vol. 65 No. 3 (2013)
- E. Shahi, C. Donati, M. Gattinara, I. Pontikaki, V. Gerloni, Primary Sjögren syndrome: report of a 10 years old girl with local edema and positivity of anti SS-A and anti SS-B autoantibodies , Reumatismo: Vol. 63 No. 2 (2011)
- V.F. Azevedo, E. Paiva, T. Tosin, A. Ferreira, A.M. Ferreira, M. Fernandes, Splenic tuberculosis in a patient with ankylosing spondylitis treated with adalimumab , Reumatismo: Vol. 63 No. 3 (2011)
- A. Romeo, S. Parazza, M. Boschi, T. Nava, C. Vanti, Manual therapy and therapeutic exercise in the treatment of osteoarthritis of the hip: a systematic review , Reumatismo: Vol. 65 No. 2 (2013)
- F.M. Perrotta, A. Scarno, A. Carboni, V. Bernardo, M. Montepaone, E. Lubrano, A. Spadaro, Assessment of subclinical atherosclerosis in ankylosing spondylitis: correlations with disease activity indices , Reumatismo: Vol. 65 No. 3 (2013)
- S. Canestri, M.C. Totaro, E. Serone, B. Tolusso, D. Frezza, E. Gremese, G. Ferraccioli, Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients , Reumatismo: Vol. 64 No. 6 (2012)
- Y. Emad, T. Gheita, H. Darweesh, P. Klooster, R. Gamal, H. Fathi, N. El-Shaarawy, M. Gamil, M. Hawass, R.M. El-Refai, H. Al-Hanafi, S. Abd-Ellatif, A. Ismail, J. Rasker, Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity , Reumatismo: Vol. 70 No. 2 (2018)
You may also start an advanced similarity search for this article.
